Boehringer Ingelheim Announces FDA Approval of Spiriva Respimat (tiotropium bromide) Inhalation Spray for the Maintenance Treatment of COPD
RIDGEFIELD, CONN. - September 26, 2014 - Boehringer Ingelheim Pharmaceuticals, Inc. announced yesterday that the U.S. Food and Drug Administration (FDA) approved SPIRIVA RESPIMAT (tiotropium bromide) inhalation spray for the long-term, once daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including bronchitis and emphysema, to reduce exacerbations in COPD patients. Boehringer Ingelheim expects SPIRIVA RESPIMAT to be available in January 2015.
SPIRIVA RESPIMAT provides a pre-measured amount of medicine in a slow-moving mist that helps patients inhale the medicine. SPIRIVA RESPIMAT was developed to actively deliver medication in a way that does not depend on how fast air is inhaled from the device.
"SPIRIVA RESPIMAT offers a new choice between a mist and a dry powder inhaler for tiotropium," said Sabine Luik, M.D., senior vice president, Medicine & Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc." Already approved in 85 countries around the world, SPIRIVA RESPIMAT reflects our scientific heritage as an industry leader in discovering and developing new treatment options for the COPD community."
Read the full press release here.